" />
Skip to main content
Navigate Up
Sign In

Mucosal and Vaccine Research Colorado
 

Welcome to MAVRC

Preventing Disease Before It Begins


Array of research equipment

The Mucosal and Vaccine Research Colorado (MAVRC) program promotes disease prevention by fostering collaborative and innovative research to understand human immunology, mucosal and vaccine biology.

Mucosal tissues are the moist surfaces of the body that provide the first line of host defense. These surfaces most often successfully exclude harmful elements from the body. However, the most common infections (pneumonia, ear and urinary tract infections, gingivitis, diarrhea and HIV/AIDS) and cancers (lung, colon, breast, and prostate) begin at the mucosa. 

Creative solutions to prevent infections, cancer and immunologic diseases can only succeed if diverse investigators work and think together across preconceived boundaries. MAVRC endeavors to identify support to integrate the talents, both conceptual and technical, of University of Colorado scientists and clinicians who recognize, and strive to combat, the problems that affect our state, our country, and our world.

__________________________________________________________________________________

NIAID Paylines for Grants -  fiscal year 2011

 

These paylines apply to applications going to the May 2011 Council Meetings.

              • R01 - New Investigator - 14%
              • R01 - Seasoned Investigator - 10%
              • R21 - 24 Overall Score

 NIAID:  Understanding Paylines and Percentiles

Starting in FY 2010, NIH changed the way it calculates overall impact scores.  For Unsolicited R01's reviewed by the NIH Center for Scientific Review, NIH converts the overall impact score into a percentile.

  • A percentile ranks your application relative to the other applications reviewed by your study section as its last three meetings
  • A percentile roughly translates to the percentage of applications receiving better overall impact score from the study section during one year
  • Percentiles range from 1 to 99 in whole numbers.  Rounding is always up, e.g., 10.1% becomes 11
  • In contrast to usual mathmatical practice, a lower number indicates a better score.

__________________________________________________________________________________

New NIH Opportunities 

    

       

RFA-AI-11-036               

  

Strategies for the Protection of Pregnant

Women and Infants Against Infectious

Diseases (R01)

The purpose of this FOA is to encourage new and innovative mechanistic studies of pathogens that impact placental function and fetal well-being, with the long-term goal of informing the development of interventions against these pathogens and reducing the burden of infection-related pregnancy loss and infant morbidity and mortality.

 Letter of Intent Due: September 13, 2011  Application Due:  October 13, 2011

 

 

           

RFA-AI-11-027                

Therapeutics for Neurotropic Biodefense

Toxins and Pathogens (R21/R33) 

To support basic to translational research focused on development of new therapeutic strategies for neurotropic intoxication or infection caused by select biodefense pathogens.

Letter of Intent Due: September 23, 2011 Application Due:  October 24, 2011

 

 

Learning Event

 

 

 

  Mucosal and Vaccine Research Colorado

  12631 East 17th Avenue, Suite 7408 • Mail Stop 8205 • Aurora, CO 80045

Program Administrator:  Carola Hagenau  Phone: 303-724-8499 • Fax: 303-724-0802 • E-mail: MAVRC@ucdenver.edu                           

  http://ucdenver.edu/MAVRC • DirectionsVisitor Parking Map                              Executive Director: Edward N. Janoff, MD   

 

University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.